Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11352361 Compounds useful as RET inhibitors

Patent 11352361 was granted and assigned to Cancer Research Technology Limited on June, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

‌

Cancer Research Technology Limited

Current Assignee

‌

Cancer Research Technology Limited

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11352361

Patent Inventor Names

Rebecca Newton0

Allan Jordan0

Bohdan Waszkowycz0

George Hynd0

Jonathan Mark Sutton0

Date of Patent

June 7, 2022

Patent Application Number

16604332

Date Filed

April 13, 2018

Patent Citations Received

‌

US Patent 11680068 Compounds useful as RET inhibitors

Patent Primary Examiner

CPC Code

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11352361 Compounds useful as RET inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API